Myriad Genetics
MYGN
190 hedge funds and large institutions have $1.06B invested in Myriad Genetics in 2020 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 70 increasing their positions, 60 reducing their positions, and 50 closing their positions.
17% more repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 60
7.37% less ownership
Funds ownership: 106.32% → 98.96% (-7.4%)
16% less funds holding
Funds holding: 227 → 190 (-37)
51% less capital invested
Capital invested by funds: $2.15B → $1.06B (-$1.1B)
53% less call options, than puts
Call options by funds: $2.69M | Put options by funds: $5.68M
64% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 50
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$28.5M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
+$25.5M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$16.4M |
| 4 |
EARNEST Partners
Atlanta,
Georgia
|
+$11.9M |
| 5 |
Invesco
Atlanta,
Georgia
|
+$7.72M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$51.4M |
| 2 |
GCM
Glenview Capital Management
New York
|
-$40.2M |
| 3 |
RCAMU
Rothschild & Co Asset Management US
Stamford,
Connecticut
|
-$24.2M |
| 4 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
-$16.7M |
| 5 |
Morgan Stanley
New York
|
-$15.7M |
MYGN Hedge Fund Activity: Q1 2020 in Review
190 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Myriad Genetics (MYGN) for Q1 2020, worth a combined $1.06B — down 51% from $2.15B a quarter earlier.
Sellers outnumbered buyers: 50 funds closed out of MYGN and 18 opened new positions — a net loss of 32 holders — while 60 trimmed existing stakes and 70 added.
The largest buyer was Camber Capital Management, adding an estimated $28.5M. The largest seller was Deutsche Bank, cutting an estimated $51.4M.
- 190 institutional investors held Myriad Genetics (MYGN) as of Q1 2020, down from 227 in Q4 2019.
- Funds reported $1.06B of Myriad Genetics stock for Q1 2020, down 51% quarter-over-quarter.
- 18 funds opened new Myriad Genetics positions in Q1 2020 and 50 closed out, a net change of -32 holders.
- The largest Myriad Genetics buyer in Q1 2020 was Camber Capital Management, an estimated $28.5M added.
- The largest Myriad Genetics seller in Q1 2020 was Deutsche Bank, an estimated $51.4M sold.
Based on aggregated 13F filings for Q1 2020.